1. Hua, Shi, Li, Hongyan, Liu, Yuguang, Cheng, Yanhao, Dai, Chao. 2018. High expression of GALNT7 promotes invasion and proliferation of glioma cells. In Oncology letters, 16, 6307-6314. doi:10.3892/ol.2018.9498. https://pubmed.ncbi.nlm.nih.gov/30405766/
2. Nie, Guo-Hui, Luo, Liang, Duan, Hong-Fang, Li, Zhao, Zhang, Wei. 2015. GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma. In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 4559-67. doi:10.1007/s13277-015-4281-6. https://pubmed.ncbi.nlm.nih.gov/26503214/
3. Berkel, Caglar, Cacan, Ercan. 2023. The expression of O-linked glycosyltransferase GALNT7 in breast cancer is dependent on estrogen-, progesterone-, and HER2-receptor status, with prognostic implications. In Glycoconjugate journal, 40, 631-644. doi:10.1007/s10719-023-10137-4. https://pubmed.ncbi.nlm.nih.gov/37947928/
4. Gao, Fei, Han, Jianjun, Jia, Li, Liu, Xiaojun, He, Xia. 2022. MiR-30c facilitates natural killer cell cytotoxicity to lung cancer through targeting GALNT7. In Genes & genomics, 45, 247-260. doi:10.1007/s13258-022-01306-0. https://pubmed.ncbi.nlm.nih.gov/36040682/
5. Wu, Haiyan, Zhou, Ruoyu, Kong, Hanxin, Li, Kunzhi, Zhang, Yunmei. 2024. Exercise Attenuates Doxorubicin-Induced Myocardial Injury by Inhibiting TSHR and Regulating Macrophage Polarization Through miR-30d-5p/GALNT7. In Journal of immunology research, 2024, 5562293. doi:10.1155/2024/5562293. https://pubmed.ncbi.nlm.nih.gov/39493373/
6. Lu, Qijue, Xu, Li, Li, Chunguang, Huang, Shengdong, Chen, Hezhong. 2016. miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer. In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 14605-14614. doi:. https://pubmed.ncbi.nlm.nih.gov/27619677/
7. Cao, Qinxue, Wang, Ning, Ren, Lu, Yang, Shaoqin, Cheng, Hailing. 2020. miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/PI3K/AKT pathway. In Cancer cell international, 20, 117. doi:10.1186/s12935-020-01209-8. https://pubmed.ncbi.nlm.nih.gov/32308562/